Rhythm (RYTM) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
130.1M
Gross Profit
116.8M
89.73%
Operating Income
-265.5M
-204.04%
Net Income
-260.6M
-200.27%
Balance Sheet Metrics
Total Assets
392.3M
Total Liabilities
227.7M
Shareholders Equity
164.5M
Debt to Equity
1.38
Cash Flow Metrics
Operating Cash Flow
-89.9M
Free Cash Flow
-113.9M
Revenue & Profitability Trend
Rhythm Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 130.1M | 77.4M | 23.6M | 3.2M | 0 |
| Cost of Goods Sold | 13.4M | 9.3M | 2.1M | 599.0K | 0 |
| Gross Profit | 116.8M | 68.1M | 21.5M | 2.6M | 0 |
| Operating Expenses | 382.3M | 252.5M | 200.7M | 172.6M | 136.6M |
| Operating Income | -265.5M | -184.4M | -179.2M | -170.1M | -136.6M |
| Pre-tax Income | -260.3M | -184.1M | -181.1M | -69.6M | -134.0M |
| Income Tax | 346.0K | 564.0K | 0 | 0 | - |
| Net Income | -260.6M | -184.7M | -181.1M | -69.6M | -134.0M |
| EPS (Diluted) | - | -$3.20 | -$3.47 | -$1.40 | -$3.04 |
Income Statement Trend
Rhythm Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 374.2M | 308.3M | 354.2M | 308.4M | 181.7M |
| Non-Current Assets | 18.1M | 24.5M | 28.2M | 21.1M | 5.4M |
| Total Assets | 392.3M | 332.7M | 382.5M | 329.5M | 187.1M |
| Liabilities | |||||
| Current Liabilities | 115.5M | 55.2M | 39.8M | 43.4M | 18.0M |
| Non-Current Liabilities | 112.2M | 107.8M | 78.4M | 1.9M | 2.6M |
| Total Liabilities | 227.7M | 163.0M | 118.2M | 45.4M | 20.5M |
| Equity | |||||
| Total Shareholders Equity | 164.5M | 169.8M | 264.3M | 284.2M | 166.5M |
Balance Sheet Composition
Rhythm Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -260.6M | -184.7M | -181.1M | -69.6M | -134.0M |
| Operating Cash Flow | -89.9M | -129.0M | -172.4M | -42.7M | -122.5M |
| Investing Activities | |||||
| Capital Expenditures | 0 | -47.0K | -281.0K | -434.0K | -214.0K |
| Investing Cash Flow | -48.2M | -5.7M | 32.0M | -64.2M | 158.5M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 174.0M | 65.8M | 203.4M | 161.7M | 0 |
| Free Cash Flow | -113.9M | -136.2M | -177.7M | -151.4M | -122.2M |
Cash Flow Trend
Rhythm Key Financial Ratios
Valuation Ratios
Forward P/E
-23.27
Price to Book
208.49
Price to Sales
28.88
PEG Ratio
-23.27
Profitability Ratios
Profit Margin
-123.28%
Operating Margin
-143.73%
Return on Equity
-150.20%
Return on Assets
-51.33%
Financial Health
Current Ratio
3.30
Debt to Equity
69.65
Beta
2.30
Per Share Data
EPS (TTM)
-$2.80
Book Value per Share
$0.30
Revenue per Share
$2.22
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| rytm | 4.0B | - | 208.49 | -150.20% | -123.28% | 69.65 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.